Table of Contents Author Guidelines Submit a Manuscript
Stem Cells International
Volume 2016, Article ID 9601493, 8 pages
http://dx.doi.org/10.1155/2016/9601493
Research Article

Dasatinib and Doxorubicin Treatment of Sarcoma Initiating Cells: A Possible New Treatment Strategy

1Department of Oncology, Aarhus University Hospital, 8000 Aarhus C, Denmark
2Department of Clinical Biochemistry, Aarhus University Hospital, 8000 Aarhus C, Denmark
3Laboratory for Molecular Endocrinology (KMEB), Department of Endocrinology, Odense University Hospital, 5000 Odense, Denmark
4Danish Stem Cell Center (DanStem), Panum Institute, University of Copenhagen, 2200 Copenhagen, Denmark

Received 15 June 2015; Revised 20 August 2015; Accepted 23 August 2015

Academic Editor: Dominik Wolf

Copyright © 2016 Ninna Aggerholm-Pedersen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. Reya, S. J. Morrison, M. F. Clarke, and I. L. Weissman, “Stem cells, cancer, and cancer stem cells,” Nature, vol. 414, no. 6859, pp. 105–111, 2001. View at Publisher · View at Google Scholar · View at Scopus
  2. N. Serakinci, P. Guldberg, J. S. Burns et al., “Adult human mesenchymal stem cell as a target for neoplastic transformation,” Oncogene, vol. 23, no. 29, pp. 5095–5098, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Jain, K. V. Sajeevan, K. G. Babu, and K. C. Lakshmaiah, “Chemotherapy in adult soft tissue sarcoma,” Indian Journal of Cancer, vol. 46, no. 4, pp. 274–287, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Chen, R. Borker, J. Ewing et al., “Epidemiology, treatment patterns, and outcomes of metastatic soft tissue sarcoma in a community-based oncology network,” Sarcoma, vol. 2014, Article ID 145764, 7 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. J. M. Stommel, A. C. Kimmelman, H. Ying et al., “Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies,” Science, vol. 318, no. 5848, pp. 287–290, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. S. N. Dumont, D. Yang, A. G. Dumont, D. Reynoso, J.-Y. Blay, and J. C. Trent, “Targeted polytherapy in small cell sarcoma and its association with doxorubicin,” Molecular Oncology, vol. 8, no. 8, pp. 1458–1468, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. J. L. Simonsen, C. Rosada, N. Serakinci et al., “Telomerase expression extends the proliferative life-span and maintains the osteogenic potential of human bone marrow stromal cells,” Nature Biotechnology, vol. 20, no. 6, pp. 592–596, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. J. S. Burns, B. M. Abdallah, P. Guldberg, J. Rygaard, H. D. Schrøder, and M. Kassem, “Tumorigenic heterogeneity in cancer stem cells evolved from long-term cultures of telomerase-immortalized human mesenchymal stem cells,” Cancer Research, vol. 65, no. 8, pp. 3126–3135, 2005. View at Google Scholar · View at Scopus
  9. J. S. Burns, B. M. Abdallah, H. D. Shrøder, and M. Kassem, “The histopathology of a human mesenchymal stem cell experimental tumor model: support for an hMSC origin for Ewing's sarcoma?” Histology and Histopathology, vol. 23, no. 10, pp. 1229–1240, 2008. View at Google Scholar · View at Scopus
  10. B. M. Abdallah, M. Haack-Sørensen, J. S. Burns et al., “Maintenance of differentiation potential of human bone marrow mesenchymal stem cells immortalized by human telomerase reverse transcriptase gene despite of extensive proliferation,” Biochemical and Biophysical Research Communications, vol. 326, no. 3, pp. 527–538, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. K. Vesely, M. Jurajda, R. Nenutil, and M. Vesela, “Expression of p53, cyclin D1 and EGFR correlates with histological grade of adult soft tissue sarcomas: a study on tissue microarrays,” Neoplasma, vol. 56, no. 3, pp. 239–244, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. O. Sato, T. Wada, A. Kawai et al., “Expression of epidermal growth factor receptor, ERBB2 and KIT in adult soft tissue sarcomas: a clinicopathologic study of 281 cases,” Cancer, vol. 103, no. 9, pp. 1881–1890, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. W. Ren, B. Korchin, Q.-S. Zhu et al., “Epidermal growth factor receptor blockade in combination with conventional chemotherapy inhibits soft tissue sarcoma cell growth in vitro and in vivo,” Clinical Cancer Research, vol. 14, no. 9, pp. 2785–2795, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. I. Ray-Coquard, A. Le Cesne, J. S. Whelan et al., “A phase II study of gefitinib for patients with advanced HER-1 expressing synovial sarcoma refractory to doxorubicin-containing regimens,” Oncologist, vol. 13, no. 4, pp. 467–473, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. M. B. Abera and M. G. Kazanietz, “Protein kinase Cα mediates erlotinib resistance in lung cancer cells,” Molecular Pharmacology, vol. 87, no. 5, pp. 832–841, 2015. View at Publisher · View at Google Scholar
  16. C. Wilson, X. Ye, T. Pham et al., “AXL inhibition sensitizes mesenchymal cancer cells to antimitotic drugs,” Cancer Research, vol. 74, no. 20, pp. 5878–5890, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. M. A. Olayioye, A. Badache, J. M. Daly, and N. E. Hynes, “An essential role for Src kinase in ErbB receptor signaling through the MAPK pathway,” Experimental Cell Research, vol. 267, no. 1, pp. 81–87, 2001. View at Publisher · View at Google Scholar · View at Scopus
  18. N. Fujioka, J. Nguyen, C. Chen et al., “Morphine-induced epidermal growth factor pathway activation in non-small cell lung cancer,” Anesthesia and Analgesia, vol. 113, no. 6, pp. 1353–1364, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. N. A. G. Lankheet, L. M. Knapen, J. H. M. Schellens, J. H. Beijnen, N. Steeghs, and A. D. R. Huitema, “Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care,” Therapeutic Drug Monitoring, vol. 36, no. 3, pp. 326–334, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. R. A. R. Villacis, S. M. Silveira, M. C. Barros-Filho et al., “Gene expression profiling in leiomyosarcomas and undifferentiated pleomorphic sarcomas: SRC as a new diagnostic marker,” PLoS ONE, vol. 9, no. 7, Article ID e102281, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. K. Ikeda, L.-H. Wang, R. Torres et al., “Discoidin domain receptor 2 interacts with Src and Shc following its activation by type I collagen,” Journal of Biological Chemistry, vol. 277, no. 21, pp. 19206–19212, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. T. Ren, W. Zhang, X. Liu et al., “Discoidin domain receptor 2 (DDR2) promotes breast cancer cell metastasis and the mechanism implicates epithelial-mesenchymal transition programme under hypoxia,” The Journal of Pathology, vol. 234, no. 4, pp. 526–537, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. J. G. van Oosterwijk, J. K. Anninga, H. Gelderblom, A.-M. Cleton-Jansen, and J. V. M. G. Bovée, “Update on targets and novel treatment options for high-grade osteosarcoma and chondrosarcoma,” Hematology/Oncology Clinics of North America, vol. 27, no. 5, pp. 1021–1048, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. D. Bonnet and J. E. Dick, “Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell,” Nature Medicine, vol. 3, no. 7, pp. 730–737, 1997. View at Publisher · View at Google Scholar · View at Scopus